Shopping Cart
- Remove All
- Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $157 | In Stock | |
5 mg | $546 | In Stock | |
10 mg | $689 | In Stock | |
25 mg | $1,080 | In Stock | |
50 mg | $1,460 | In Stock | |
100 mg | $1,960 | In Stock |
Description | Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer. |
In vitro | METHODS: Human breast cancer cells BT-474 were treated with Trastuzumab (0.01-10 µg/mL) for 72 h. Cell viability was determined by MTS Assay. RESULTS: The antiproliferative effect of Trastuzumab was observed at concentrations as low as 0.5 µg/mL, with a stabilizing level of approximately 10 µg/mL.[1] METHODS: CHO-K6, CHO-EGFR and CHO-HER3 cells were treated with Trastuzumab (0.1-10 µg/mL) for 5-60 min, and binding to HER receptors was detected by Immunofluorescence. RESULTS: Trastuzumab binds only to HER2, but not to EGFR and HER3. [2] |
In vivo | METHODS: To test the in vivo antitumor activity, Trastuzumab (5 µg/g) was administered intraperitoneally once a week for seven doses to nude mice harboring human mammary carcinoma tumor JIMT-1. RESULTS: Trastuzumab had a significant inhibitory effect on tumor growth on days 21-56. After stopping administration, tumors began to grow in two nude mice whose tumors were palpable earlier. [3] |
Molecular Weight | Approximately 145.53 kDa |
Cas No. | 180288-69-1 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.